301301 Stock Overview
Engages in the research and development, and industrialization of biological fermentation technology in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 301301 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Yili Chuanning Biotechnology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.34 |
| 52 Week High | CN¥18.33 |
| 52 Week Low | CN¥6.94 |
| Beta | 0 |
| 1 Month Change | -3.59% |
| 3 Month Change | 12.80% |
| 1 Year Change | 44.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301301 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.4% | -3.0% | -2.1% |
| 1Y | 44.8% | -19.0% | 9.8% |
Return vs Industry: 301301 exceeded the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 301301 exceeded the CN Market which returned 11.8% over the past year.
Price Volatility
| 301301 volatility | |
|---|---|
| 301301 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 301301 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301301's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 2,881 | Xuheng Deng | www.klcnsw.com |
Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid.
Yili Chuanning Biotechnology Co.,Ltd. Fundamentals Summary
| 301301 fundamental statistics | |
|---|---|
| Market cap | CN¥27.48b |
| Earnings (TTM) | CN¥1.38b |
| Revenue (TTM) | CN¥5.70b |
20.0x
P/E Ratio4.8x
P/S RatioIs 301301 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301301 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.70b |
| Cost of Revenue | CN¥3.69b |
| Gross Profit | CN¥2.00b |
| Other Expenses | CN¥628.21m |
| Earnings | CN¥1.38b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 35.18% |
| Net Profit Margin | 24.15% |
| Debt/Equity Ratio | 18.6% |
How did 301301 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:50 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yili Chuanning Biotechnology Co.,Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Chao Li | Citic Securities Co., Ltd. |
| Ban Wang | Minsheng Securities Co. |